Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Shree Ganesh Remedies Limited, at its meeting on May 19, 2025, approved the audited standalone and consolidated financial results for Q4 and full year ended March 31, 2025. The statutory auditors (Chaudhary Shah & Associates LLP) issued an unmodified (clean) opinion on the results. Standalone revenue from operations declined to ₹10,859.65 lakhs from ₹12,589.54 lakhs in FY24, a drop of about 13.7% year-on-year, while standalone net profit fell to ₹1,625.17 lakhs from ₹2,111.78 lakhs (about 23% decline). Q4 FY25 was weaker, with revenue down roughly 35% YoY. The Board also appointed M/s. Prachi Bansal & Associates as Secretarial Auditors for FY24-25 and a five-year term (FY25-26 to FY29-30), and re-appointed M/s. S N D K & Associates LLP as Internal Auditors for FY25-26.
A clean audit opinion and continuity in auditor appointments are positives, but the sharp revenue and profit decline, especially in Q4, may weigh on near-term investor sentiment. Shareholders should track whether the weakness reverses in coming quarters.